Powered by Google

Sorry, something went wrong and the translator is not available.

Sorry, something went wrong with the translation request.

loading Translating

Vincristine (Oncovin, Vincasar)
Revised: August 24, 2023
Published: March 21, 2004

(For veterinary information only)

The size of the tablet/medication is NOT an indication of a proper dose. Never administer any drug without your veterinarian's input. Serious side effects or death can occur if you use drugs on your pet without your veterinarian's advice. 

It is our policy not to give dosing information over the internet.

Brand Name: Oncovin, Vincasar

Available as injectable


Because they are transported everywhere that the bloodstream can take them, cancer chemotherapy drugs have the ability to reach tumors that are inaccessible to the surgeon and undetectable to the diagnostician. In order to preserve the normal cells, anti-cancer drugs must affect activities that involve cancer cells but spare normal cells. Since cancer cells divide rapidly and uncontrollably while normal cells divide more slowly and in response to controlled cellular messages, most anti-cancer drugs target cell division. As a cell divides, microscopic protein rods called microtubules pull the two cell halves apart. These structural proteins must work properly or cell division cannot occur. Vincristine is a member of the vinca alkaloid class of chemotherapy drugs. It is extracted from the Vinca rosea plant and is a microtubule poison.

How This Medication Is Used

Vincristine is chiefly used as one drug in multi-drug combination protocols against lymphoid and round cell tumors. Lymphoma, mast cell tumors, and transmissible venereal tumors often include vincristine in their protocols.

Separate from its chemotherapy use, vincristine has the unexplained ability to cause a sudden release of platelets (blood clotting cells) from the bone marrow. For this reason, vincristine is commonly included in the treatment of immune-mediated thrombocytopenia

Vincristine is typically used as a weekly injection.

Side Effects

Vincristine must absolutely be given intravenously. Vincristine is highly irritating to the soft tissues, and if it is not given intravenously, where the bloodstream rapidly carries it away and dilutes it within the body’s blood volume, it will cause what is called a tissue slough. This means the soft tissues will die and fall away, leaving a large sore. Unlike the tissue sloughs of doxorubicin, a vincristine slough will eventually heal, but it will require bandaging and be a source of discomfort.

Vincristine has some potential for neurologic side effects, especially in cats. A neurologically based constipation may result, particularly in cats. Difficulty coordinating the feet may be seen. Humans report paresthesias, which include odd sensations such as occur when your foot is “asleep.”

Vincristine use will increase blood uric acid levels, rarely a concern in animals, but could be a problem in dogs with a history of uric acid bladder stones.

Dogs with the MDR1 mutation will likely require dose adjustments. This mutation is common in collie-related breeds and affects the way numerous drugs are metabolized. Genetic testing may be indicated to determine a patient's MDR1 status before therapy with this medication. See below for more information on this.

Interactions With Other Drugs

The neurologic toxicities noted above are more likely to occur when vincristine is used in combination with L-Asparaginase, which is not an uncommon combination in the treatment of lymphoma.

Concerns and Cautions

Vincristine is not able to pass through the blood/brain barrier and thus cannot treat tumors in the nervous system.

Vincristine is removed from the body by the liver. If the pet has poor liver function, a dose adjustment may be needed, or a different drug may be selected. A guideline that has been published is to cut the vincristine dose by 50 percent in patients with a total bilirubin level of higher than 2 mg/dl.

Vincristine should not be used in pregnancy and may cause sterility in males.

Vincristine is also a drug whose metabolism depends on the P-glycoprotein. Collie-type breeds tend to have a mutation of the P-glycoprotein gene that could make them sensitive to the neurologic side effects of this drug. (The P-glycoprotein normally provides a block to keep drugs out of the central nervous system; if the glycoprotein is non-functional, drugs that normally do not access the nervous system can then do so, causing toxicity.) There is now a test for P-glycoprotein mutation so that sensitive dogs can be identified. This is a DNA test using an oral swab. Test kits can be ordered directly from the Washington State University Veterinary School.

Border collies appear to have an increased risk for vincristine-related bone marrow suppression that is separate from the P-glycoprotein mutation described above.

Vaccinations may not be effective in patients on a vincristine injection protocol.

The content of this site is owned by Veterinary Information Network (VIN®), and its reproduction and distribution may only be done with VIN®'s express permission.

The information contained here is for general purposes only and is not a substitute for advice from your veterinarian. Any reliance you place on such information is strictly at your own risk.

Links to non-VIN websites do not imply a recommendation or endorsement by VIN® of the views or content contained within those sites.